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Pemphigus vulgaris (PV) is an autoimmune blistering
disease of the skin and is caused by autoantibodies against
desmoglein 3 (Dsg3) on epidermal keratinocytes. Because
the production of autoantibodies is presumably T cell
dependent, Dsg3-specific T cell reactivity was investi-
gated in 14 PV patients and 12 healthy donors. Peripheral
blood mononuclear cells from seven PV patients with
active disease showed a primary in vitro response to a
recombinant protein containing the extracellular portion
(EC1–5) of Dsg3, whereas two of seven PV patients in
remission or under immunosuppressive treatment exhib-
ited only secondary (2°) or tertiary (3°) T cell responses
to Dsg3. T cell responses to Dsg3 were also observed in
four of 12 healthy individuals upon 2° or 3° stimulation
with Dsg3. Both PV patients and healthy responders were
Pemphigus vulgaris (PV) is a life-threatening autoimmuneblistering disease caused by auto-antibodies (Ab) againstdesmoglein 3 (Dsg3), a desmosomal glycoprotein onepidermal keratinocytes (Stanley, 1989; Amagai et al, 1991,1992). The auto-Ab bind to distinct sites of the extracellular
portion (EC1–5) of Dsg3 and cause epidermal cells to come apart
(Anhalt et al, 1982; Stanley, 1989; Amagai et al, 1992, 1994). The
resulting clinical picture with extensive blister formation of all stratified
squamous epithelia (skin and mucous membranes) can be devastating.
The purpose of this study was to identify and characterize T cell
responses to Dsg3, the auto-antigen of PV, in PV patients and healthy
individuals. Current concepts strongly suggest that auto-antigen-specific
T cells play a crucial role in the initiation and perpetuation of both
Ab-and cell-mediated autoimmue diseases (Anhalt et al, 1982; Stanley,
1989). Evidence for the presence of auto-antigen-specific T cells has
been provided in other human autoimmune diseases associated with
pathogenic auto-Ab, such as myasthenia gravis (Brocke et al, 1988),
insulin-dependent diabetes mellitus (Rossini et al, 1985; Kaufmann
et al, 1992), autoimmune thyroiditis (Roitt, 1956), and multiple sclerosis
(Kumar et al, 1989; Martin et al, 1993; Fredrikson et al, 1993). Recogni-
tion of epitopes of Dsg3 may thus be crucial for the initiation and
perpetuation of Dsg3-specific T cell responses providing help to the
B cells that produce Dsg3-specific auto-Ab. Involvement of CD41 T
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either positive for DRb1*0402 – which is highly prevalent
in PV – or positive for DR11 alleles homologous to
DRb1*0402. Two CD4F Dsg3-specific T cell lines and
12 T cell clones from two PV patients and two CD4F T
cell lines and eight T cell clones from two normals were
also stimulated by a Dsg3 protein devoid of the EC2–3
(∆N1), suggesting that epitopes were located in the EC1,
EC4, and/or EC5. Using Dsg3 peptides, one immuno-
dominant peptide (residues 161–177) was also identified
in the EC2. These observations demonstrate that T cell
responses to Dsg3 can be detected in PV patients and in
healthy donors carrying major histocompatibility class II
alleles identical or similar to those highly prevalent in
PV. Key words: autoimmunity/peptides/T lymphocytes. J Invest
Dermatol 110:62–66, 1998
lymphocytes in the pathogenesis of PV has been further suggested by
the strong association of PV with the major histocompatibility complex
(MHC) II phenotypes HLA-DRβ1*0402 and HLA-DR14 (Ahmed
et al, 1990, 1991).
In this study, two recombinant Dsg3 proteins containing the extracel-
lular portion (EC1–5) of Dsg3 (Amagai et al, 1994, 1996) were used
to identify Dsg3-specific T cell responses in PV patients and healthy
controls. Furthermore, T cell epitopes of the EC1–5 of Dsg3 were
identified using recombinant deletion proteins of Dsg3 and a panel of
111 overlapping synthetic peptides representing portions of the EC1–
5 of Dsg3.
MATERIALS AND METHODS
PV patients and healthy donors The 14 PV patients studied were either
untreated at the onset of active disease (n 5 7), in clinical remission (n 5 2),
or treated with immunosuppressive drugs (n 5 5). The 12 control subjects were
either healthy relatives of PV patients (n 5 4), randomly chosen healthy
individuals (n 5 6), or patients with bullous pemphigoid (n 5 2). All patients
and controls gave informed consent to participate in this study. HLA typing
was performed using serology (HLA-A, -B, -C) or denaturing gradient gel
electrophoresis of polymerase chain reaction products of specific oligonucleotide
priming (HLA-DR, -DQ, DRw). The most common MHC II alleles in the
14 PV patients were HLA-DRβ1*0402 (n 5 9), HLA-DR14 (n 5 3), and
HLA-DR11 (n 5 3). Five of the 12 healthy controls were HLA-DR111 and
one was HLA-DRβ1*04021.
Reagents Human IgG1 (kappa and lambda chains) was obtained from Sigma
(St. Louis, MO). Tetanus toxoid was a gift from Lederle Laboratories (Pearl
River, NY).
Production and purification of recombinant Dsg3 proteins expressed
by baculovirus-infected insect cells The recombinant Dsg proteins used
were: PVIg, a protein consisting of the EC1–5 of Dsg3 linked to the constant
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region of human IgG1 (Amagai et al, 1992); ∆N1, a deletion mutant of PVIg
devoid of residues 119–439 (unpublished); PFIg, EC1–5 of Dsg1 linked to the
constant region of human IgG1 (Amagai et al, 1996); and PVhis, a fusion
protein consisting of the EC1–5 of Dsg3 linked to E-tag and histidine tag (Ishii
et al, 1997). Recombinant baculovirus encoding these proteins was amplified
in SF9 insect cells as described previously (Amagai et al, 1994). For the
production of recombinant protein, 21 3 106 High-Five insect cells were
inoculated with culture supernatant (SN) containing recombinant baculovirus
at a multiplicity of infection greater than 10. Culture SN of baculovirus-infected
insect cells were then collected after 3–4 d and recombinant proteins were
purified from culture SN by affinity chromatography: PVIg, ∆N1, and PFIg
proteins by passage over protein A agarose (Pierce, Rockford, IL) and PVhis
protein by passage over Nickel agarose (His-bind buffer kit; Novagen, Madison,
WI) according to the manufacturers’ instructions.
Culture media Peripheral blood mononuclear cells (PBMC) and T cell lines
were cultured in RPMI 1640 (Gibco BRL, Gaithersburg, MD) with 10%
pooled human serum (Sigma), 100 U penicillin per ml, 100 µg streptomycin
per ml, 20 mM L-glutamine, and HEPES buffer (all from Gibco BRL). Culture
media with 10% fetal calf serum (Biofluids, Gaithersburg, MD) were exclusively
used for the expansion of Dsg3-specific T cell clones (after stimulation with
1% phytohemagglutinin, Gibco BRL). SF9 insect cells (Invitrogen, San Diego,
CA) were maintained in Grace’s medium (Gibco BRL) with 10% fetal
calf serum, penicillin/streptomycin, and L-glutamine; High-Five insect cells
(Invitrogen) were cultured in Ex-Cell 405 (JRH Scientific, Berkeley, CA) with
penicillin/streptomycin and L-glutamine.
Peptides One hundred and eleven 17 mer peptides staggered by five residues
were synthesized to encompass the EC1–5 of Dsg3 (Amagai et al, 1991).
Peptides 1–88 (starting at the NH2-terminal end of Dsg3) were synthesized by
the pepset technique (Chiron Mimotopes, San Diego, CA) resulting in a purity
greater than 65% as determined by high performance liquid chromotography.
These peptides were acetylated at the NH2-terminal end and contained a
diketopiperazine moiety at the COOH-terminal end. Peptides 89–111 were
synthesized using Fmoc chemistry (Quality Control Biologicals, Boston, MA)
and were at least 70% pure. These peptides were acetylated at the NH2-terminal
and amidated at the COOH-terminal end. Lyophilized peptides were dissolved
in H2O at 2 mg per ml and were stored at –70°C. Each individual peptide was
used at 20 µg per ml leading to a cumulative concentration of 160 µg per ml
when the peptides were used as pools of eight.
Dsg3- and tetanus toxoid-specific T cell lines and clones Paired samples
of 3 3 105 PBMC from PV patients and healthy donors were cultured in
200 µl cultures (Costar, Cambridge, MA) with PVIg (25 µg per ml) or tetanus
toxoid (4 Lf per ml) and received 20 U interleukin (IL)-2 per ml (Boehringer,
Nutley, NJ) after 7 d. PVIg-or tetanus toxoid-specific T cells were periodically
restimulated with PVIg or tetanus toxoid and autologous x-irradiated (5000 R)
PBMC and expanded with IL-2, resulting in PVIg-and tetanus toxoid-specific
T cell lines after the 4° antigen stimulation. The specificities of the 1°, 2°, 3°
in vitro-stimulation with antigen were determined by the incorporation of
[3H]thymidine in cultures with T cells, PVIg, or tetanus toxoid and autologous
x-irradiated PBMC as antigen-presenting cells (APC). After the 4° antigen
stimulation, CD41 PVIg-specific T cell lines were established from the PV
patients 8 and 9 and the healthy controls C6 and C11. Eight PVIg-specific T
cell clones were generated from the parental T cell line PV8, three clones from
PV9, six clones from C6, and three T cell clones from C11 by standard limiting
dilution techniques.
Proliferation assays Samples of 5 3 104 T cells were cultured in triplicate
with 5 3 104 x-irradiated (5000 R) autologous PBMC in 200 µl cultures
(Costar) for 72 h at 37°C in 5% CO2. T cell proliferation was determined by
the uptake of [3H]thymidine (Amersham, Arlington Heights, IL) and was
expressed as a stimulation index (SI 5 [3H]thymidine uptake in cultures with
antigen and cultures without antigen). A SI . 2 was arbitrarily considered as a
threshold value because proliferative T cell responses to Dsg3 of PV patients
with active disease exceeded this value compared with those of normals (except
for one individual). The paired Student’s t test was used to analyze significant
differences between T cell proliferation in cultures with and without antigen.
Assays with PBMC from PV patients were generally set up together with
PBMC from at least one healthy donor (internal control).
Cytokine production of Dsg3-specific T cells Two 3 106 T cells per ml
were stimulated with 10 ng phorbol myristate acetate (Sigma) per ml and 1 µg
ionomycin (Sigma) per ml. The immunoreactivities of 24 h culture SN for IL-
2, IL-4, IL-10, and interferon-γ were determined in duplicate by enzyme-
linked immunosorbent assay (R&D, Berkeley, CA).
Figure 1. Proliferative response of PBMC from PV patients and healthy
donors to Dsg3. The proliferation of PBMC from seven PV patients (m) and
five healthy donors (n) cultured with PVIg (extracellular portion of Dsg3;
25 µg per ml) was determined by the uptake of [3H]thymidine (3H-TdR) after
7 d (1° culture). An SI . 2 was considered as a threshold value. Background
proliferation ranged from 92 to 31,703 cpm in the 1° cultures, from 92 to
12,299 cpm in the 2° cultures, and from 231 to 8263 in the 3° cultures. PVIg-
responsive PBMC were expanded with human IL-2 (20 U per ml) and were
then restimulated with PVIg and x-irradiated autologous PBMC as APC (2°
culture). For the 3° culture, PVIg-specific T cells from the 2° culture were
restimulated with PVIg and autologous PBMC as APC after expansion with
IL-2.
RESULTS
Proliferative response of PBMC from PV patients and normals
to Dsg3 PBMC from seven PV patients with active disease exhibited
1° in vitro T cell responses to PVIg (EC1–5 of Dsg3) (Fig 1). Five of
seven PV patients were DRβ1*04021 and two were DRβ1*11041.
None of seven PV patients receiving immunosuppressive treatment or
in clinical remission exhibited 1° Dsg3-specific T cell responses (SI 5
0.3–1.9; p , 0.57), but two of these seven PV patients showed T cell
proliferation in 2° or 3° cultures with PVIg. PBMC from one of 12
healthy controls (C11: DRβ1*1101,1102) showed a 1° response to
PVIg (SI 5 2.9; p , 0.04). PBMC from three additional healthy
controls (C4: DRβ1*0402–; C5: DRβ1*1101–; C6: DRβ1*1104–)
showed a T cell response upon 2° stimulation with PVIg (SI 5 2.7–
6.4; p , 0.03) (Fig 1). All of the Dsg3-responsive healthy donors were
not related to PV patients except for C6 who was the daughter of PV
patient 9 (DRβ1*0402, 1104). T cell stimulation in the 1° cultures
with Dsg3 was significantly increased in the studied PV patients
compared with the control group (p , 0.03). There was, however,
no significant difference between PV patients and normals in the 2°
and 3° cultures with PVIg (Fig 1). PBMC from eight healthy donors
did not proliferate in 1° cultures with PFIg, a recombinant protein
consisting of the EC1–5 of Dsg1 (pemphigus foliaceus antigen) (data
not shown).
Specificity and MHC II restriction of PVIg-propagated T
cells Four CD41 T cell lines from PV8, PV9, C6, and C11 that
were equally stimulated by PVIg and PVhis (EC1–5 of Dsg3) (Fig 2)
were restricted by the MHC II molecule DRβ1*0402 or several DR11
alleles homologous to DRβ1*0402).1 The three CD41 T cell lines
from PV8 (DRβ1*1104,1404), C6 (DRβ1*1104,-), and C11
(DRβ1*1101,1102) responded to PVIg with DRβ1*1101,11021
1Hertl M, Karr RW, Amagai M, Katz ST: Heterogeneous MHCII restriction
pattern of autoreactive desmoglein 3-specific T cell responses in pemphigus
vulgaris patients and normals, submitted.
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Figure 2. Specificity of Dsg3-responsive T cell lines. PVIg-specific T cell
lines from PV patients (PV) 8 (j) and 9 (u) and the healthy donors (CTRL)
C6 (j) and C11 (j) were cultured with human IgG1 (hIgG1), PVIg, or PVhis
(all used at 20 µg per ml). T cell proliferation was determined by the uptake
of [3H]thymidine and is expressed as cpm 6 SD. Background proliferation
ranged from 575 to 2356 cpm. *p , 0.004, **p , 0.001, ***p , 0.002,
****p , 0.003, compared with the corresponding control.
Figure 3. Epitope specificity of a CD41 Dsg3-specific T cell line from
donor C11. A Dsg3-specific CD41 T cell line was cultured with x-irradiated
autologous PBMC as APC and the particular antigen for 72 h, and [3H]thymidine
was added for the final 18 h. T cell proliferation is expressed as cpm (mean
6 SD). PVIg, PFIg, and ∆N1 were used at 20 µg per ml. Seventeen mer
peptides were used in pools of eight (p1–88) or separately (p33, residues 161–
177) at 20 µg per ml (each). The proliferative response of T cell line C11 to
peptide 33 (0.5–100 µg per ml) was determined in a separate experiment (inset).
*p , 0.001, **p , 0.02, ***p , 0.004, ****p , 0.007, compared with the
corresponding control.
PBMC as APC (data not shown). The Dsg3-specific T cell line from
PV9 (DRβ1*0402,1104) proliferated to PVIg with DRβ1*04021
PBMC as APC (data not shown).
Epitope recognition of Dsg3-specific T cells Four CD41 PVIg-
responsive T cell lines from PV8, PV9, C6, and C11 and T cell clones
generated from these T cell lines (PV8, n 5 8; PV9, n 5 3; C6, n 5
6; C11, n 5 3) were co-cultured with ∆N1, a deletion mutant of
PVIg devoid of the EC2–3 and a panel of 17-mer Dsg3 peptides.
The CD41 Dsg3-specific T cell line from C11 (DRβ1*1101,1102)
proliferated in response to PVIg and to ∆N1, strongly suggesting that
one immunodominant peptide was located in the EC1, EC4, and/or
EC5 (Fig 3). C11 was also stimulated by the pool of peptides 33–40
(p33–40) and p33 (residues 161–177) that is located in the EC2 of
Dsg3 (Fig 3, inset). The proliferative response of C11 to p33 was
reproducible, because preparations of p33 manufactured by two differ-
ent companies stimulated this T cell line to a similar extent (data not
shown). The amino acid sequence of p33 is LLSRNTGEVRTL-
TNSLD. CD41 T cell clones generated from the T cell line from
Figure 4. Differential epitope specificity of two CD41 T cell clones
from donor C11. T cell clones C11.29 (j) and C11.32 (j) generated from
the Dsg3-specific T cell line C11 (Fig 3) were cultured with irradiated PBMC
as APC alone, with PVIg, ∆N1, PFIg, the Dsg3 peptides 33–40 (p33–40), or
p33 (residues 161–177) (all at 20 µg per ml) for 72 h, and T cell proliferation
was determined by the incorporation of [3H]thymidine, expressed as cpm
(mean 6 SD). *p , 0.04, **p , 0.004, ***p , 0.008, compared with the
corresponding control.
Figure 5. Epitope specificity of a CD41 Dsg3-responsive T cell line
from the PV patient 8. CD41 Dsg3-specific T cells from patient 8 were
cultured with x-irradiated PBMC as APC and hIgG1, PVIg, ∆N1, PFIg, and
PVhis (all at 20 µg per ml) for 72 h. T cell proliferation was determined by the
uptake of [3H]thymidine and is expressed as cpm (mean 6 SD). T cells were
also co-cultured with 17 mer peptides encompassing EC1–5 of Dsg3 that were
added either in pools of eight (p1–88) or separately (p89–111) at 20 µg per ml
(each). The proliferative T cell responses shown on the upper and lower
portions of the graph are derived from two separate experiments. *p , 0.004,
**p , 0.001, ***p , 0.006, compared with the corresponding control.
C11 showed a heterogeneous epitope specificity (Fig 4). Clone C11.32
was stimulated by PVIg and by p33 (residing in the EC2), but not by
∆N1 (devoid of the EC2–3); this proliferative response was restricted
by DRβ1*1102.1 T cell clone C11.29 was stimulated by ∆N1 but not
by p33. In contrast, p33 did not stimulate PBMC from five PV
patients (two of which were DRβ1*04021) upon 1° culture and a
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Figure 6. Differential cytokine production of Dsg3-specific T cell clones
from the PV patients 8 and 9 and the healthy donor C11. Dsg3-specific
T cell clones from patient 8 (1–4), patient 9 (5–6), and C11 (7–9) were
stimulated with phorbol Myristate acetate and ionomycin, and culture SN were
collected after 24 h. The immunoreactivities of culture SN for IL-2, interferon-
γ, IL-4, and IL-10 were determined by enzyme-linked immunosorbent assay
and are expressed in pg per ml 6 SD.
CD41 Dsg3-specific T cell line from the DRβ1*04021 PV patient
PV9 (data not shown).
Despite a vigorous response to PVIg and to ∆N1, CD41 T cell
lines and clones from the PV patients 8 (Fig 5; n 5 9) and 9 (n 5 3;
data not shown) failed to respond to any of the 17 mer peptides that
encompassed the EC1–5 of Dsg3. Similarly, five Dsg3-specific CD41 T
cell clones from the donor C6 responded to PVhis (SI 5 2.5–16.5;
p , 0.03) but not to the overlapping 17 mer peptides encompassing
EC1–5 of Dsg3 (SI 5 0.4–1.5; p , 0.87).
Effect of Dsg3 peptides on tetanus toxoid-specific T cell
proliferation To exclude inhibitory effets exerted by the Dsg3
peptides, their effect on tetanus toxoid-specific T cell responses of
Dsg3-responsive individuals was investigated. The proliferation of
a tetanus toxoid-specific CD41 T cell line from PV9 (SI 5 12.9,
p , 0.001) was not altered significantly by either PVIg (SI 5 11.5) or
by Dsg3 peptides 1–111 (pooled at eight, each at 20 µg per ml; SI 5
10.2–15.2).
Proliferative response of Dsg3-specific T cells to Dsg1 (pem-
phigus foliaceus antigen) The EC1–3 of Dsg3 are highly homolog-
ous (75–80%) to the EC1–3 of Dsg1, the auto-antigen of pemphigus
foliaceus, a bullous autoimmune disease closely related to PV (Koch
and Franke, 1994; Emery et al, 1995). The cross-reactivity of Dsg3-
specific T cells to PFIg, a fusion protein containing the EC1–5 of
Dsg1, was thus investigated in vitro. A Dsg3-specific T cell line (Fig 5)
and four clones (SI 5 14.5–110, p , 0.004) from PV8, a CD41 T
cell line and two clones from PV9 (SI 5 2.5–4.2, p , 0.007), and a
CD41 T cell line (Fig 3) and two clones (SI 5 6.4–8.6, p , 0.017)
from donor C11 showed a proliferative response to PFIg. In contrast,
a CD41 Dsg1 (PFIg)-specific T cell line from a patient with pemphigus
foliaceus was stimulated by PFIg (SI 5 3.8, p , 0.001), but not
by PVIg (SI 5 1.5, p , 0.75) or by the synthetic peptides 1–111
encompassing the EC1–5 of Dsg3 (SI 5 0.8–1.4, p , 0.85).
Dsg3-specific CD81 T cell responses A Dsg3-responsive T cell
line from patient 9 containing both CD41 and CD81 T cells was
separated by negative selection into highly purified (.95%) CD41 and
CD81 fractions. Both, the CD41 T cell fraction (SI 5 29.6,
p , 0.001) and the CD81 T cell fraction (SI 5 4.8, p , 0.001)
proliferated in response to PVIg but not to IgG1 (SI 5 0.9–1.6,
p , 0.57).
Cytokines secreted by Dsg3-specific T cells SN were collected
from cultures with Dsg3-specific T cells 24 h after stimulation with
PMA and ionomycin, and the immunoreactivities for IL-2, IL-4, IL-
10, and interferon-γ were determined by enzyme-linked immunosorb-
ent assay (Fig 6). Dsg3-specific T cell lines and clones from the PV
patients 8 and 9 produced high amounts of interferon-γ and little IL-
2 and IL-10, but no IL-4. In contrast, Dsg3-specific T cells from
donor C11 secreted IL-4, IL-10, and IL-2, but no interferon-γ.
DISCUSSION
This study demonstrates that PV patients with active disease exhibit
1° in vitro CD41 T cell responses to the EC1–5 of Dsg3. Dsg3-specific
CD41 T cell responses were also detected in four healthy donors who
were positive for DRβ1*0402 (n 5 1) or for several DR11 alleles
(n 5 3) that are highly homologous to DRβ1*0402. Carriers of
particular MHC II alleles thus seem to be genetically at risk of
developing Dsg3-specific T cell responses.
These observations differ in several aspects from the results of a
recent study by Lin et al who identified T cell responses to proteins
representing regions of the EC1–5 of Dsg3 in most of their studied
PV patients but not in normals (Lin et al, 1997). The disease activity
of their PV patients was, however, not further defined and thus – as
in our study – could not be correlated with Dsg3-specific T cell
reactivity. A major difference between this study and the study by Lin
et al is the T cell reactivity to Dsg3 in some of our healthy donors that
was detected upon repeated in vitro restimulation of PBMC with Dsg3.
In vitro priming with Dsg3 was unlikely because PBMC from one
normal also showed a significant 1° response to Dsg3. This Dsg3-
responsive normal, whose identity is not known to the authors, carried
the allele DRβ1*1102 that is highly homologous to the pemphigus-
associated allele DRβ1*0402. The other Dsg3-responsive normals also
had MHC II alleles similar or identical to those prevalent in PV. This
finding is interesting in light of previous observations by Ahmed et al
who demonstrated low-titer Ab in relatives of PV patients and
hypothesized a predisposition to development of PV in this immuno-
genetically susceptible group (Ahmed et al, 1993). Unfortunately, the
study by Lin et al does not provide any information concerning the
MHC II haplotypes of their healthy nonresponsive controls. Finally,
in contrast to their exclusive identification of CD41 T cell responses
to Dsg3, CD81 T cells specific for Dsg3 were also identified in one
PV patient. There are various possibilities as to how Dsg3 released
from epidermal keratinocytes may be presented to CD81 T cells in
association with MHC I molecules. Exogenous Dsg3 may be subject
to phago- or endocytosis and Dsg3 peptides generated in proteasomes
may then bind to MHC I in the endoplasmic reticulum (cytosolic
pathway). Alternatively, Dsg3 peptides may be generated after
internalization of exogenous Dsg3 into phagosomes and may associate
there with recycled or newly synthesized MHC I (noncytosolic
pathway) (reviewed in Rock, 1996).
Most of the Dsg3-specific T cell populations were stimulated by
∆N1, a recombinant Dsg3 protein devoid of the EC2–3, suggesting
that T cell epitope(s) of Dsg3 were located in the EC1, EC4, and/or
EC5. Dsg3-specific T cells were also co-cultured with a panel of
overlapping peptides that encompassed the EC1–5 of Dsg3. This
strategy led to the identification of one epitope (p33, residues 161–
177) in the EC2 of Dsg3. Despite a vigorous response to the
recombinant Dsg3 protein, most Dsg3-specific T cell populations were
not stimulated by any of the Dsg3 peptides. This may be for
several reasons: (i) a particular immunodominant epitope was not fully
contained within a single peptide; (ii) post-translational modifications
of the Dsg3 auto-antigen were not conserved in the synthetic peptides
as recently reported by Pette et al (1990); (iii) the peptides were toxic
even though they did not inhibit tetanus toxoid-specific T cell
proliferation and phytohemagglutinin-induced mitogenesis (not
shown); and (iv) peptide concentrations in vitro were too low because
of poor solubility. We favor a fifth possibility recently reported by
Diepolder et al (1996) who demonstrated that TH1 cells in particular
can be anergized in vitro by their immunodominant epitopes.
Our findings with Dsg3 peptides are in contrast to a recent study
by Wucherpfennig and Strominger (1995) who identified DRβ1*0402-
associated Dsg3 peptides based on the charge of key residues. In their
study, T cell responses were detected to two of these peptides (DG190–
204, DG206–220) in DRβ1*04021 PV patients. In our study, six
Dsg3 peptides that were almost identical to those identified by
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Wucherpfennig et al (p6, p10, p29, p32, p41, p91) did not stimulate a
DRβ1*0402-restricted Dsg3-specific T cell line (data not shown).
Interestingly, the DRβ1*1102-restricted epitope p33 (residues 161–
177 of Dsg3) of this study is highly homologous to the DRβ1*0402-
restricted Dsg3 peptide DG206–220 (Wucherpfennig and Strominger,
1995). The DRβ1*1102 allele shows a high degree of similarity with
the DRβ1*0402 molecule for the residues 67, 70, and 71 of the third
hypervariable region that are crucial binding peptide sites (Wucherpfen-
nig et al, 1995). There is strong evidence that p33 binds to DRβ1*1102
because murine L cells transfected with DRβ1*1102 acted as sufficient
APC for the p33-driven proliferative response of the T cell clone
C11.32 (manuscript submitted). The biologic significance of p33 in
PV is unclear because T cells from three DRβ1*04021 PV patients
were not stimulated by this peptide in vitro.
Dsg3-specific T cells from two PV patients produced TH1 cytokines
whereas T cell clones from a healthy donor produced TH2 cytokines.
This is in line with recent studies that implicated TH1 cells as effector
cells in the Ab-mediated autoimune diseases autoimmune thyroiditis
(Del Prete et al, 1989; Swain et al, 1990) and insulin-dependent diabetes
mellitus (Liblau et al, 1995). Our findings, however, are in contrast to
recent studies (Wucherpfennig et al, 1995; Lin et al, 1997) that have
identified TH2-like Dsg3-specific T cell responses in PV.
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